Incyte (INCY) has moved to deepen its use of artificial intelligence in drug discovery, broadening collaborations with Genesis Molecular AI and Edison Scientific to plug advanced platforms directly into its research and development workflows.
See our latest analysis for Incyte.
Despite the recent AI collaboration headlines, the stock’s 30 day share price return of 2.65% contrasts with a decline of 3.65% over 90 days, while the 1 year total shareholder return of 51.23% points to stronger longer term momentum.
If AI driven drug discovery is on your radar, it may be worth broadening your watchlist with other potential opportunities from the 34 healthcare AI stocks.
With Incyte trading at $97.16 and sitting roughly 11% below an average analyst price target of $107.96, the key question is whether this reflects an undervalued AI driven pipeline or whether the market already prices in future growth.
Most Popular Narrative: 10.5% Undervalued
At $97.16, the most followed narrative places Incyte’s fair value at $108.50, building a case around pipeline execution and post patent cliff earnings resilience.
The upcoming launches and label expansions of innovative therapies like Opzelura (ruxolitinib cream), povorcitinib, and Niktimvo in high-value indications such as atopic dermatitis, vitiligo, hidradenitis suppurativa (HS), and GVHD, along with a late-stage pipeline of targeted drugs, are viewed as positioning Incyte to benefit from demand for advanced immunology and oncology treatments in aging populations, which is expected to support revenue and earnings.
This higher fair value is based on those product and pipeline expectations, even as forecasts point to declines in earnings and revenue and a richer future P/E than many biotech peers.
Result: Fair Value of $108.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this narrative could be knocked off course if Jakafi patents roll off faster than expected or late stage assets fail to deliver commercially relevant data.
Find out about the key risks to this Incyte narrative.
Another View: DCF Paints A Harsher Picture
While the consensus narrative points to a fair value of $108.50, Simply Wall St’s DCF model suggests something very different, with an estimated future cash flow value of $50.66. That implies Incyte trades at roughly double this DCF outcome. This raises the question: which perspective carries more weight, the pipeline or the cash flows?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Incyte for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed messages from the narratives so far? With both risks and potential rewards on the table, move quickly to review the details and weigh the 2 key rewards and 1 important warning sign.
Looking For More Investment Ideas?
If you are weighing Incyte’s story, do not stop here. Broaden your opportunity set with structured stock ideas that match the kind of portfolio you want to build.
- Target potential mispricings by scanning a curated group of companies trading below fair value using the 49 high quality undervalued stocks.
- Strengthen your income stream by focusing on companies with robust cash generation and yields from the 10 dividend fortresses.
- Dial down portfolio risk by concentrating on companies with resilient balance sheets and quality fundamentals highlighted in the solid balance sheet and fundamentals stocks screener (46 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com